Research by topic

Philosophy (Philosophy of Medicine, Philosophy of Science, Ethics)

  1. La Caze A, Colyvan M. (In Press). A challenge for evidence-based policy. Axiomathes
  2. La Caze A. (In Press). The hierarchy of evidence and quantum theory. Journal of Clinical Epidemiology
  3. La Caze A. (2013). Why randomized interventional studies. Journal of Medicine and Philosophy. 38:352–368. Preprint
  4. La Caze A. (2011). The role of basic science in evidence-based medicine. Biology and Philosophy, 26(1):81–98. Preprint
  5. La Caze A, Duffull, S. (2011). Estimating risk from underpowered, but statistically significant, studies: Was APPROVe on TARGET? Journal of Clinical Pharmacy and Therapeutics (online first).
  6. La Caze A, Djulbegovic B, Senn S. (2011). What does randomisation acheive? Evidence-based Medicine (online first).
  7. La Caze A. (2009). Evidence Based Medicine must be…. Journal of Medicine and Philosophy, 34:509–527. Preprint
  8. La Caze A. (2008). Evidence Based Medicine can’t be …. Social Epistemology, 22(4):353–370. Preprint
  9. La Caze A. (2008). A problem for achieving informed choice. Theoretical Medicine and Bioethics, 29:255–265. Preprint
  10. La Caze A. (2005). Does pharmacogenomics provide an ethical challenge to the utilization of cost-effectiveness analysis by public healthcare systems? Pharmacoeconomics, 23(5):445-7.


  1. Foot H, La Caze A, Gujral G, Cottrell N. (In Press). The necessity–concerns framework predicts adherence to medication in multiple illness conditions: A meta-analysis *Patient Education and Counselling
  2. La Caze A, Gujral G, Cottrell N. (2014). How do we better translate adherence research into improvements in patient care? International Journal of Clinical Pharmacy. 36(1):10–14.
  3. Nguyen T-M-U, La Caze A, Cottrell WN. (2013). What are validated self-report adherence scales really measuring?: a systematic review. British Journal of Clinical Pharmacology. Forthcoming.
  4. La Caze A, Gujral G, Cottrell N. (2012). Adherence and beliefs Journal of Pharmacy Practice and Research 42(1):6–7.

Quality Use of Medicines

  1. Iyer P, McFarland R, La Caze A. (In Press) Expectations and responsibilities regarding the sale of complementary medicines in pharmacies: perspectives of consumers and pharmacy support staff. International Journal of Pharmacy Practice
  2. Burrows J, Dall’Alba G, La Caze A. (In Press) Becoming pharmacists: Students’ understanding of pharmacy practice at graduation from an Australian University. Currents in Pharmacy Teaching and Learning
  3. Tan A, Emmerton L, Hattingh HL, La Caze A. (2015). Funding issues and options for pharmacists providing sessional services to rural hospitals in Australia Australian Health Review (Online First)
  4. Niyomnaitham S, Page A, La Caze A, Whitfield K, Smith AJ. (2014). Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings BMC Health Services Research 14:151.
  5. Tan A, Emmerton L, Hattingh HL, La Caze A. (2014). Cross-sector, sessional employment of pharmacists in rural hospitals in Australia and New Zealand: a qualitative study exploring pharmacists’ perceptions and experiences. BMC Health Services Research 14:567
  6. Tio J, La Caze A, Cottrell W. (2007). Ascertaining consumer perspectives on medication information sources using a modified repertory grid technique. Pharmacy World Science, 29:73-80.
  7. Fiori S, Souzani S, D’Amore R, Behan K, Cutts C, La Caze A. (2005). Support Needs of Supply Nurses in Rural and Remote Queensland. Australian Journal of Rural Health, 13:10-3.
  8. Cutts C, La Caze A, Tett S. (2003). Variations in demographics and risk factors of patient populations prescribed cyclo-oxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs. Journal of Pharmacy Practice and Research, 33(1):70-73.
  9. Cutts C, La Caze A, Tett S. (2002). A clinical audit of the prescribing of COX-2 inhibitors in Australian general practice. British Journal of Clinical Pharmacology, 54:522-7
  10. Cutts C, La Caze A. (2002). Using clinical audit to identify and change high-risk NSAID prescribing. Australian Family Physician, 31(6):590-2.